COSMO PHARMACEUTICALS NV (C43.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:C43 - NL0011832936 - Common Stock
48.8 EUR
-1.2 (-2.4%)
C43 gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 55 industry peers in the Pharmaceuticals industry. C43 scores excellent points on both the profitability and health parts. This is a solid base for a good stock. C43 is growing strongly while it also seems undervalued. This is an interesting combination C43 also has an excellent dividend rating. These ratings could make C43 a good candidate for value and dividend and growth and quality investing.
1. Profitability
1.1 Basic Checks
- C43 had positive earnings in the past year.
- C43 had a positive operating cash flow in the past year.
- The reported net income has been mixed in the past 5 years: C43 reported negative net income in multiple years.
- Each year in the past 5 years C43 had a positive operating cash flow.
1.2 Ratios
- The Return On Assets of C43 (20.60%) is better than 94.23% of its industry peers.
- C43's Return On Equity of 26.74% is fine compared to the rest of the industry. C43 outperforms 76.92% of its industry peers.
- The Return On Invested Capital of C43 (21.60%) is better than 88.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.6% | ||
| ROE | 26.74% | ||
| ROIC | 21.6% |
ROA(3y)6.94%
ROA(5y)4.44%
ROE(3y)9.26%
ROE(5y)6.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With an excellent Profit Margin value of 49.94%, C43 belongs to the best of the industry, outperforming 98.08% of the companies in the same industry.
- In the last couple of years the Profit Margin of C43 has grown nicely.
- C43's Operating Margin of 55.81% is amongst the best of the industry. C43 outperforms 100.00% of its industry peers.
- C43's Operating Margin has improved in the last couple of years.
- Looking at the Gross Margin, with a value of 83.00%, C43 belongs to the top of the industry, outperforming 86.54% of the companies in the same industry.
- C43's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 55.81% | ||
| PM (TTM) | 49.94% | ||
| GM | 83% |
OM growth 3Y48.45%
OM growth 5YN/A
PM growth 3Y14.46%
PM growth 5YN/A
GM growth 3Y18.94%
GM growth 5Y6.74%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), C43 is creating value.
- C43 has less shares outstanding than it did 1 year ago.
- Compared to 5 years ago, C43 has more shares outstanding
- Compared to 1 year ago, C43 has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 5.80 indicates that C43 is not in any danger for bankruptcy at the moment.
- The Altman-Z score of C43 (5.80) is better than 90.38% of its industry peers.
- C43 has a debt to FCF ratio of 0.01. This is a very positive value and a sign of high solvency as it would only need 0.01 years to pay back of all of its debts.
- The Debt to FCF ratio of C43 (0.01) is better than 98.08% of its industry peers.
- A Debt/Equity ratio of 0.00 indicates that C43 is not too dependend on debt financing.
- The Debt to Equity ratio of C43 (0.00) is better than 94.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.01 | ||
| Altman-Z | 5.8 |
ROIC/WACC2.81
WACC7.68%
2.3 Liquidity
- A Current Ratio of 4.19 indicates that C43 has no problem at all paying its short term obligations.
- The Current ratio of C43 (4.19) is better than 96.15% of its industry peers.
- A Quick Ratio of 3.91 indicates that C43 has no problem at all paying its short term obligations.
- The Quick ratio of C43 (3.91) is better than 96.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.19 | ||
| Quick Ratio | 3.91 |
3. Growth
3.1 Past
- C43 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1315.29%, which is quite impressive.
- The Earnings Per Share has been growing by 85.20% on average over the past years. This is a very strong growth
- The Revenue has grown by 187.55% in the past year. This is a very strong growth!
- Measured over the past years, C43 shows a very strong growth in Revenue. The Revenue has been growing by 33.68% on average per year.
EPS 1Y (TTM)1315.29%
EPS 3Y85.2%
EPS 5YN/A
EPS Q2Q%551.15%
Revenue 1Y (TTM)187.55%
Revenue growth 3Y60.05%
Revenue growth 5Y33.68%
Sales Q2Q%165.79%
3.2 Future
- Based on estimates for the next years, C43 will show a very strong growth in Earnings Per Share. The EPS will grow by 29.02% on average per year.
- The Revenue is expected to grow by 22.67% on average over the next years. This is a very strong growth
EPS Next Y-23.67%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
EPS Next 5Y29.02%
Revenue Next Year-19.4%
Revenue Next 2Y-19.53%
Revenue Next 3Y-19.24%
Revenue Next 5Y22.67%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 5.98, the valuation of C43 can be described as very cheap.
- C43's Price/Earnings ratio is rather cheap when compared to the industry. C43 is cheaper than 92.31% of the companies in the same industry.
- The average S&P500 Price/Earnings ratio is at 27.21. C43 is valued rather cheaply when compared to this.
- Based on the Price/Forward Earnings ratio of 8.09, the valuation of C43 can be described as reasonable.
- Based on the Price/Forward Earnings ratio, C43 is valued cheaper than 84.62% of the companies in the same industry.
- C43 is valuated cheaply when we compare the Price/Forward Earnings ratio to 25.98, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.98 | ||
| Fwd PE | 8.09 |
4.2 Price Multiples
- C43's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. C43 is cheaper than 96.15% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, C43 is valued cheaply inside the industry as 94.23% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.46 | ||
| EV/EBITDA | 3.83 |
4.3 Compensation for Growth
- The excellent profitability rating of C43 may justify a higher PE ratio.
- C43's earnings are expected to decrease with -27.68% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
5. Dividend
5.1 Amount
- C43 has a Yearly Dividend Yield of 3.85%. Purely for dividend investing, there may be better candidates out there.
- The stock price of C43 dropped by -28.24% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
- Compared to an average industry Dividend Yield of 1.62, C43 pays a bit more dividend than its industry peers.
- C43's Dividend Yield is rather good when compared to the S&P500 average which is at 1.81.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.85% |
5.2 History
- On average, the dividend of C43 grows each year by 7.41%, which is quite nice.
Dividend Growth(5Y)7.41%
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
- 24.09% of the earnings are spent on dividend by C43. This is a low number and sustainable payout ratio.
- The dividend of C43 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP24.09%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
COSMO PHARMACEUTICALS NV / C43.DE FAQ
What is the fundamental rating for C43 stock?
ChartMill assigns a fundamental rating of 9 / 10 to C43.DE.
What is the valuation status for C43 stock?
ChartMill assigns a valuation rating of 8 / 10 to COSMO PHARMACEUTICALS NV (C43.DE). This can be considered as Undervalued.
What is the profitability of C43 stock?
COSMO PHARMACEUTICALS NV (C43.DE) has a profitability rating of 8 / 10.
Can you provide the expected EPS growth for C43 stock?
The Earnings per Share (EPS) of COSMO PHARMACEUTICALS NV (C43.DE) is expected to decline by -23.67% in the next year.
How sustainable is the dividend of COSMO PHARMACEUTICALS NV (C43.DE) stock?
The dividend rating of COSMO PHARMACEUTICALS NV (C43.DE) is 8 / 10 and the dividend payout ratio is 24.09%.